During the 9th Microbiome Movement Summit Europe, held recently in Barcelona (Spain) Microbiomepost sat down with Professor Jacques Ravel, from University of Maryland School of Medicine and LUCA Biologics. In this interview, he discusses his latest research and therapeutic innovations in the field of vaginal microbiome modulation. Drawing on over a decade of research, Ravel and his team have developed a deep understanding of the ecology, composition, and function of the vaginal microbiome—knowledge that has guided the creation of novel live biotherapeutic products aimed at restoring an optimal microbial balance.

These interventions are centered around Lactobacillus crispatus, widely recognized as the most beneficial and protective species within the vaginal ecosystem. Several formulations have been developed, including products containing six or fifteen strains of L. crispatus, and a symbiotic formulation that combines three strains with nutritional components to support their growth. Two clinical trials are currently underway: one in Boston and South Africa focused on preventing recurrent bacterial vaginosis, and another evaluating the symbiotic’s ability to reestablish L. crispatus-dominant microbiota.

Early results show high safety and promising efficacy, with regulatory bodies such as the FDA acknowledging the low-risk profile of these products. Professor Ravel emphasizes that these advances may soon offer healthcare providers new, evidence-based tools for improving women’s health through microbiome restoration.